Precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide. “This is one of many projects in our pipeline that demonstrates Precipio’s value to pharma and biotech companies as they take their research from the bench to the clinical setting.” Mr. The work that our team has done with our multiplexed ICE COLD-PCR puts these types of development projects right in our wheel-house”, stated Stephen Miller, Chief Commercial Officer of Precipio. “We are extremely pleased to be working with the team at H3 Biomedicine on this second project. During the project, Precipio will develop nine amplicons within the genes of interest and focus on the amplification and multiplexing of the mutations of interest. The second development project between the companies will focus on the development of multiplexed PCR assays for FGFR3, PIK3CA, HRAS, TERT and PLEKHS1. The first project between H3 and Precipio was the development of multiplexed PCR assays for PIK3CA and ESR1 genes. H3 currently has three compounds in phase I development. H3 embraces a novel business model in which it collaborates with Eisai to create a prolific drug discovery engine and partnership platform. As a clinical-stage biopharmaceutical company, H3 uniquely leverages their distinct insights from cancer genomics and real-life patient data to advance their projects to clinical proof of concept and beyond. H3 Biomedicine was launched in 2011 with an unprecedented $200 million funding commitment from Eisai, a leading global pharmaceutical company pharmaceuticals company, plus additional funding for clinical programs. The panel would be used by H3 Biomedicine for their ongoing clinical development programs.
The panel will include a pre-amplification multiplexed PCR that will amplify targeted regions of the key genes of interest.
(NASDAQ: PRPO), announced the initiation of a second development project with H3 Biomedicine that will include the creation of a targeted gene panel. NEW HAVEN, CT, (June 25th, 2019) - Specialty diagnostics company Precipio, Inc. Precipio and H3 Biomedicine Sign Second Development AgreementĬompanies to create a panel amplifying targeted regions of key cancer genes
0 kommentar(er)
